Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model

Rachel A. Crossley; Alyssa Matz; D. E.W. Terry; Ashley Kalinauskas; Nicole Faucette; Brad Poff; Lawrence K. Silbart; Mark A. Suckow

doi:10.21873/anticanres.13275

Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model

Rachel A. Crossley
, Alyssa Matz
, D. E.W. Terry
, Ashley Kalinauskas
, Nicole Faucette
, Brad Poff
, Lawrence K. Silbart
, Mark A. Suckow

Biomedical Engineering

Producción científica: Article › revisión exhaustiva

11 Citas (Scopus)

Resumen

Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.

Idioma original	English
Páginas (desde-hasta)	1699-1703
Número de páginas	5
Publicación	Anticancer Research
Volumen	39
N.º	4
DOI	https://doi.org/10.21873/anticanres.13275
Estado	Published - abr 2019

Nota bibliográfica

Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.

Financiación

The Authors thank Alexus Maschinot, Lauren Klein and Meaghan Bolles for all their help with tumor processing; Isabella Raymond for assisting with data analysis; the Technological Incubation Program (TIP) at the University of Connecticut for providing wet and dry labs, offices and co-working spaces in Farmington, Connecticut as well as access to instrumentation, research services and collaboration with scientific experts; and Connecticut Innovations and UConn Innovation Fund for funding this project.

Financiadores
UConn Innovation Fund
Connecticut Innovations
Vehicle Technologies Program
Connecticut 06520 Yale University New Haven Connecticut 06520
CCNU-QLPL Innovation Fund

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Oncology
Cancer Research

Acceder al documento

10.21873/anticanres.13275

Otros archivos y enlaces

Citar esto

@article{e052ad4c76f14de595bf45226c31c2be,

title = "Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model",

abstract = "Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12\%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.",

keywords = "Autologous vaccine, Cancer immunotherapy, Dog, Model, Safety",

author = "Crossley, \{Rachel A.\} and Alyssa Matz and Terry, \{D. E.W.\} and Ashley Kalinauskas and Nicole Faucette and Brad Poff and Silbart, \{Lawrence K.\} and Suckow, \{Mark A.\}",

year = "2019",

month = apr,

doi = "10.21873/anticanres.13275",

language = "English",

volume = "39",

pages = "1699--1703",

number = "4",

}

TY - JOUR

T1 - Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model

AU - Crossley, Rachel A.

AU - Matz, Alyssa

AU - Terry, D. E.W.

AU - Kalinauskas, Ashley

AU - Faucette, Nicole

AU - Poff, Brad

AU - Silbart, Lawrence K.

AU - Suckow, Mark A.

PY - 2019/4

Y1 - 2019/4

N2 - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.

AB - Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.

KW - Autologous vaccine

KW - Cancer immunotherapy

KW - Dog

KW - Model

KW - Safety

UR - https://www.scopus.com/pages/publications/85064488179

UR - https://www.scopus.com/pages/publications/85064488179#tab=citedBy

U2 - 10.21873/anticanres.13275

DO - 10.21873/anticanres.13275

M3 - Article

C2 - 30952708

AN - SCOPUS:85064488179

SN - 0250-7005

VL - 39

SP - 1699

EP - 1703

JO - Anticancer Research

JF - Anticancer Research

IS - 4

ER -

Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto